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Abstract
Background and aims: Understanding the determinants of Crohn's disease (CD) patients'
health-related quality of life (HRQOL) may facilitate interventions that improve HRQOL.
Therefore, we systematically assessed determinants of HRQOL in adult CD patients.
Methods: The databases PubMed, EMBASE, the Cochrane Library, PsycINFO and CINAHL were
searched for English abstracts, related to socio-demographic, psychological, clinical and
treatment-related determinants of HRQOL in CD disease. Two independent reviewers extracted
study characteristics and assessed the methodological quality according the criteria of Hayden
et al. The main outcome was the number of studies showing a statistically significant association
between the above-mentioned determinants and HRQOL. A meta-analysis was performed to
quantify the relationship between disease activity and HRQOL.
Results: Of the 2060 articles identified, 29 eligible studies were included. The majority of
studies were cross-sectional and had a moderate to high quality. Data on psychological
determinants were scarce. Work disability, increased disease activity, number of relapses,
corticosteroid treatment and hospitalization rate were significantly associated with a lower
HRQOL in the majority of included studies. Biological treatment positively influenced HRQOL.
The pooled data on the association between disease activity and HRQOL resulted in a weighed
mean correlation coefficient of −0.61 (CI −0.65 to −0.57).
Conclusions: HRQOL of adult CD patients is consistently determined by markers of active
disease, including work disability, increased disease activity, number of relapses, biological
treatment and hospitalization rate. As disease activity contributed to only 37% of HRQOL, there
remains a need for additional, possibly modifiable, determinants. These determinants may
refine possibilities to improve HRQOL.nt of Gastroenterology and Hepa
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Crohn's disease (CD) is a chronic, progressive and potentially
disabling disease. CD patients often deal with unpredictable
and potentially debilitating symptoms, including diarrhoea,
fatigue and urgency. In addition, they require long-term
treatment with frequent adverse effects, the need of surgery
and hospitalizations.1 Therefore, CD patients report a lower
HRQOL compared with healthy individuals.2
HRQOL represents the functional effect of an illness and its
consequent therapy upon a patient, as perceived by the
patient. It encompasses several dimensions of life, including
physical functioning, psychosocial functioning, role function-
ing, mental health and general health perceptions.3 HRQOL is
determined by socio-demographic, clinical and psychological
and treatment-related determinants.4,5 Although disease
activity is an important determinant of HRQOL in CD, even
asymptomatic patients report a lower HRQOL, suggesting a
role for other determinants.6,7
A comprehensive understanding of the above-mentioned
determinants of CD patients' HRQOL may facilitate clinicians
in clinical decision making, defining risk groups and allowing
more accurate prediction of HRQOL.8 This latter is especially
relevant when choosing between two interventions with an
equal clinical efficacy or when treating asymptomatic
patients.9
In two previous reviews, clinical determinants (mainly
disease activity) and psychosocial determinants of HRQOL in
CD have been meticulously described — however none have
performed a systematic search strategy.4,5 This may have
resulted in an incomplete retrieval of articles, thereby
biasing results. In addition, the methodological quality of
included studies has not been ascertained, making it
difficult to interpret and compare results.Therefore, we conducted a systematic review to assess
and critically appraise the socio-demographic, clinical,
psychological and treatment-related factors determining
HRQOL in adult CD patients.2. Material & methods
This systematic review was conducted in line with the
Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) statement.102.1. Search strategy (Supplementary; Table 1)
In collaborationwith a librarian a search strategywas designed
to identify articles concerning determinants of HRQOL in adult
CD. PubMed (since 1966), EMBASE (since 1966), Cochrane
Library (since 1996), PsycInfo (since 1960) and CINAHL (since
1982) were systematically searched for titles and abstracts
published between inception date of the database and July
9th, 2012. The search strategy contained a combination of
keywords (and their synonyms) and Medical Subject Headings
(MESH)/EMTREES (in the case of EMBASE), including “Crohn's
disease”, “determinant”, and “health-related quality of life”.
Both search strategy and search filter were modified for each
database. The search strategy was supplemented with
reference tracking from all included studies, relevant reviews
and by using Web of Science.2.2. Study selection
Titles and abstracts were identified as potentially eligible by
two independent reviewers [KA, MH]. Titles and abstracts
95Determinants of HRQOL in Crohn's diseasemeeting the following inclusion criteria were selected for
full-article review:
1. English language article
2. Population: adult Crohn's disease patients (≥18 years)
3. Outcome: health-related quality of life measured with a
validated instrument (Table 1)
4. Determinant: any reported determinant related with HRQOL
5. Article published in a peer reviewed journal.
Case reports, case series (b50 patients), editorials, com-
mentaries, economic evaluation studies, diagnostic studies,
experimental studies, validation studies, induction trials,
trials not correcting for relevant covariates, and qualitative
studies were excluded. Review articles were excluded as
well – however – their reference lists were searched for
eligible articles. All retrieved full-text articles were again
independently reviewed by the reviewers [KA, MH], according
to the same predefined inclusion and exclusion criteria. When
consensus regarding the eligibility could not be accomplished,
agreement was obtained through discussions with a third
arbiter [HF].
2.3. Quality appraisal
A quality appraisal was performed in order to minimize bias
and improve the reliability of our findings. Two reviewers [KA,
MH] independently assessed the quality of each study by
scoring 33 items divided into six sources of bias: study
participation, study attrition, prognostic factormeasurement,
outcome measurement, confounding measurement and anal-
ysis (Supplementary; Table 2).11 Bias was considered present
if the majority of items within a potential source of bias
pointed in this direction. The quality of the study was rated
“high” if there was low ormoderate risk of bias in all sources of
bias. The quality of a study was rated “moderate” if there was
a high risk of bias in one source. The quality of a study wasTable 1 Disease-specific and generic health-related quality
of life instruments used in patients with Crohn's disease.
Disease-specific HRQOL questionnaire
Cleveland Clinic Questionnaire Inflammatory bowel
Inflammatory Bowel Disease Questionnaire 32
(IBDQ-32, -36, -9)
McMaster IBDQ
Rating Form of Inflammatory bowel disease Pattern
Concerns (RFIPC)
Short IBDQ (SIBDQ)
Ulcerative Colitis and Crohn’s Disease Health Status Scales
Generic HRQOL questionnaire
Euroqol-5D (EQ-5D)
Nottingham Health Profile (NHP)
Psychological General Well Being Scale (PGWB)
Quality of Well-Being Index (QWB)
Short form 36, -12, -20 (SF-36, -12 or -20)
Sickness Impact Profile (SIP)
Time trade-offrated “low” if there was a high risk of bias in at least two
sources. Differences in quality appraisal between the re-
viewers were evaluated. When consensus could not be
accomplished, agreement was obtained through discussions
with a third arbiter [HF].
2.4. Data synthesis and analysis
Of all studies both reviewers extracted data concerning study
characteristics and associations between determinants and
HRQOL. All studies were reviewed for information about
any reported socio-demographic, clinical, psychological and
treatment-related determinants of both generic and disease-
specific HRQOL. When possible, determinants that seemed to
describe similar characteristics were merged into one factor
(e.g. disease duration and time since diagnosis). The main
outcome was the frequency of studies showing a significant
association between these determinants and total HRQOL.
Determinants that were measured, but not included in the
univariate or multivariate analysis, were classified as “not
assessed”. Disparities in results between the reviewers were
discussed and if necessary, discussed with the arbiter.
Given the heterogeneity in the study design we stratified
for cross-sectional studies and prospective studies (including
randomized controlled trials) and separately assessed the
associations within these strata. Given the relatively high
number of cross-sectional studies, we further stratified for
cross-sectional studies with either a low or moderate to high
risk of bias.
Data on the association between disease activity and
HRQOL were pooled by using R statistical software version
2.13.2. Heterogeneity of the studies was evaluated by using
the Cochrane Q-test.12
3. Results
3.1. Search strategy and selection criteria (Fig. 1)
The search strategy yielded 2060 published articles. Removal
of all duplicates resulted in 1610 articles that were screened on
title and abstract following the predefined inclusion and
exclusion criteria. Incorrect study design and mixed IBD
population were the main reasons for exclusion. In total, 1339
articles were excluded, leaving 217 for full-text screening.
After full-text review, 27 studies were included in the
systematic review.13–39 Consensus between the two indepen-
dent reviewers [KA, MH] was reached in 83% of cases.
Reference tracking retrieved two additional articles.40,41
3.2. Baseline characteristics (Table 2)
Of the 29 studies, nine studies utilized data from three study
populations. Four studies, of which three were published by
Bernklev et al.16–18 and one by Høivik et al.29, utilized data
from the Inflammatory Bowel South-Eastern Norway (IBSEN)
cohort. Høivik et al.'s study was considered as an original study
as they analysed a subgroup of CD patients after ten years of
follow-up, whereas the remaining three studies analysed data
from IBD patients after five years of follow-up.29 In addition,
Casellas et al. published three studies utilizing data from the
Figure 1 Flowchart showing the search strategy (July 9th 2012).
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from the same South-Limburg Cohort.34,35 Therefore, 24
original studies remained, which were suitable for extracting
study characteristics.13–16,19–22,25–33,35–41
Most studies originated from Europe (15/24;
63%),14–16,19–22,28–31,35–37,39 others were performed in the
USA,13,25,38 Canada,33 Australia,27 or in multiple nations
worldwide.26,32,40,41 Most studies had a cross-sectional
design (11/24; 46%).20,22,25,27,30,31,33,36–39 Other types of
study design were: cohort studies (5/24; 21%),15,16,19,29,34
case–control studies (4/24; 17%)13,14,21,28 and randomized
controlled trials (4/24; 17%).26,32,40,41 Seventeen out of 24
studies (67%) were multicentre studies,14,16,19–22,26,27,29,32,35–41
and all studies recruited outpatients, of which nine studies
(38%) also recruited inpatients.19,20,22,25,26,32,33,40,41 Sample
sizes varied between 52 and 628 patients, with a majority
of females (3,576/5,735; 62%) and with mean/median
ages ranging from 29 to 45 years.13–16,19,20,22,25–33,35–41
Disease duration varied from six months to twenty
years.13,14,16,19,21,22,25–31,36,37,39–41
With regard to the HRQOLmeasures, most studies employed
both generic and disease-specific HRQOL measures (13/24;
54%).14,16,19,22,25–27,29,30,32,37,40,41 The most frequently used
disease-specific and generic measures were the IBDQ (15/24;61%)16,20–22,26–32,35,37,40,41 and the Short Form-36 (13/24;
54%),14–16,19,22,26,29,30,32,37,38,40,41 respectively (Table 2).
Associations between determinants and HRQOL were
mainly analysed using multivariate statistics (16/24;
75%)14,16,19–22,25,27,29–31,35–39 of which multiple linear or
logistic regression analysis was the most frequently used
statistical method (9/16; 56%).16,19–22,29,30,37,393.3. Critical appraisal (Table 3,
Supplementary; Table 2)
Although some studies utilized data from the same study
population,16–18,22–24,34,35 studies differed regarding
reporting and presentation of the results. Therefore, each
of the 29 studies was assessed separately.
The overall interobserver agreement regarding quality
assessment (risk of bias) was 90%. Twelve studies were
considered to be of high quality (“low risk of
bias”),13,16–18,20–23,29,34,37,38 15 studies were considered to be
of moderate quality,14,19,24–28,30–32,35,36,39–41 and two studies
were considered to be of low quality (“high risk of bias).15,33
With regard to each of the six sources of bias, method-
ological shortcomings most frequently observed were: no
97Determinants of HRQOL in Crohn's diseaseclear description of recruitment methods (item 1c, Supple-
mentary; Table 2), no information about dropouts (item 2b),
no information about missing data for prognostic factors
(item 3d), no information about standardized methods and
outcome measurement for all participants (item 4c),
incomplete data for potential confounders (item 5a), and
no description of a conceptual model, supporting the
analytic strategy (item 6b).
3.4. Determinants of HRQOL
Instead of overall HRQOL, one study used different
domains of HRQOL as outcome measures.33 Therefore this
study was excluded, leaving 23 studies for further
analysis.13–16,19–22,25–32,35–41
3.4.1. Socio-demographic determinants (Fig. 2)
For all studies reporting a significant association between
any one socio-demographic determinant (except work
disability) and HRQOL there were at least as many studies
reporting no significant association between that determi-
nant and HRQOL. As reported by four articles, female gender
was found to be significantly associated with a lower
HRQOL.16,19,22,37 Work disability was reported twice,13,16
smoking status (smoking versus non-smoking) was reported
twice,19,35 and age once,21 as having a significant impact on
total HRQOL. Being female, of older age, being a smoker and
reporting IBD-related work disability adversely affected
HRQOL.
3.4.2. Psychological determinants
Two studies examined the association between psycho-
logical distress, personality traits and disease-specific
HRQOL. Boye et al. found that “social conformity” (decent,
keeping order, doing things right and keeping social norms at
a high level) was significantly associated with HRQOL.20 Van
der Eijk et al. showed that psychological distress, including
anxiety and depression, and the occurrence of stressful life
events all had a significant negative impact on HRQOL.39
3.4.3. Clinical determinants (Fig. 3)
With regard to disease activity and the number of
relapses, there were more studies reporting a significant
than a non-significant association with HRQOL. HRQOL was
negatively influenced by an increased disease activity in ten
studies16,19,21,22,27,29,34,36,37,39 and by an increased relapse
rate in two studies.18,22 Other clinical determinants found to
be significantly associated with HRQOL were extra-intestinal
manifestations36 and shorter disease duration.31
3.4.4. Treatment-related determinants (Fig. 4)
With regard to biological treatment and CD-related
hospitalizations, there were more studies reporting a signif-
icant than a non-significant association with HRQOL. HRQOL
was negatively influenced by CD-related hospitalizations in
two studies,19,22 whereas HRQOL was positively influenced by
biological treatment, including infliximab, adalimumab,
natalizumab and certolizumab in four studies.26,32,40,41 In
four out of nine studies HRQOL was negatively associated with
corticosteroid treatment.18,19,34,37When stratifying for cross-sectional
studies20,22,25,27,30,31,33,36–39 and prospective stud-
ies15,16,19,26,29,32,34,40,41, it was found that female gender,
work disability and increased disease activity were consis-
tently associated with a lower HRQOL in both strata. Only
prospective studies reported a significant association be-
tween disability and HRQOL16 and between biological
treatment and HRQOL.26,32,40,41 When stratifying for
cross-sectional studies with either a low20,22,37,38 or moder-
ate to high risk of bias,25,27,30,31,33,36,39 no discrepancies
were found regarding determinant-HRQOL associations be-
tween these strata.
3.5. Meta-analysis
Six studies reported a correlation coefficient for the
association between disease activity and overall HRQOL
and were included for meta-analysis.17,24,27,28,31,36 Although
there was a slight difference in the instruments used to
assess disease activity and HRQOL, data seemed comparable
and thus eligible for pooling of results. In a random-effects
model, the weighted mean correlation found was of −0.61
(95% CI −0.654 to −0.5684). The total variability due to
heterogeneity was 75.27% (p = 0.0016).
4. Discussion
This systematic review of 29 studies, including 24 original
studies with a total of 5735 participants, is the first systematic
review assessing the determinants of HRQOL in adult patients
with CD. Overall, the methodological quality of these studies
was moderate to high, indicating that there was a low to
moderate risk of biased results. HRQOL was consistently
impaired by work disability, increased disease activity,
number of relapses and hospitalization rate. Biological
treatment was significantly associated with an improved
HRQOL. Disease activity contributed to 37% of patients'
HRQOL. There was a paucity of psychological data, which
precluded us from identifying consistent associations between
psychological factors and generic or disease-specific HRQOL.
To date, two iterative reviews have carefully summarized
data on determinants of HRQOL in the mixed IBD popula-
tion.4,5 One review particularly assessed the influence of
disease activity on HRQOL,4 whereas the other assessed the
influence of psychosocial factors on HRQOL.5
In line with our results, Cohen et al. found that HRQOL
was impaired in CD patients with clinically active disease,
and that disease activity was negatively correlated with
HRQOL. Contrary to our results, Cohen et al. also found a
negative association between surgery and the HRQOL of CD
patients.4 This negative association was only reported in one
study, assessing the long-term prognosis of CD patients.21
Other included studies did not report this negative associ-
ation. Possibly, in these studies the post-operative follow-up
period was too short to reveal a decreased HRQOL. In
addition, HRQOL appeared to improve shortly after surgery,
but not in the long term.42 This is consistent with the fact
that in most studies disease activity eventually recurs after
surgery.43–45
Sainsbury et al. conducted a search for studies
which evaluated psychological, social and demographic
Table 2 Characteristics of included studies (n = 29).
Article Study characteristics Characteristics CD participants Determinant HRQOL
First author
Year of
Publication
Country
Reference
Design Setting Follow-up,
years
Sample
size
Mean/
median
age,
years
(SD, IQR)
Sex Ratio,
M/F
Mean/median
disease
duration,
years
(SD, IQR)
Determinant Measure Questionnaire
IBD CD
Ananthakrishnan
2008
USA
[13]
CCS Tertiary
hospital
– 185 185 42.8 ±
14.1
82/103 13.7 ± 10.9 Demographics NS SIBDQ
Clinical data HBI
Psychiatric
comorbidity
DSM-IV
Work disability
Andersson P.
2003
SE
[14]
CCS Multicentre
Outpatients
– 383 127 44
(18–78)
56/71 16 (8–25) Socio-demographics Interview SF-36
PGWBDisease activity CDAI
Self-perceived
general health
VAS
Banovic I.
2010
FR
[15]
PC Outpatients 1 52 52 41.1 ±
12.5
23/29 NS Socio-demographics NS SF-36
Disease activity CDAI
Fatigue MFI
Sleep disturbances ISI, PSQI
Anxiety, depression HADS
Bernklev T.
2006
NO
[16]
PC Multicentre
Outpatients
IBSEN Cohort
– 495 161 38.6 ±
15.5
49%
femalea
5 Socio-demographics Interview SF
IBDQSick leave,
unemployment,
disability
Interview
Clinical data Interview
Bernklev T.
2004
NO
[17]
PC Multicentre
Outpatients
IBSEN Cohort
– 497 169 38.6 ±
15.5
83/86 5 Socio-demographics Interview IBDQ-32
Clinical data Interview,
Vienna
Bernklev T.
2005
NO
[18]
PC Multicentre
Outpatients
IBSEN Cohort
– 497 169 38.6 ±
15.5
83/86 5 Socio-demographics Interview IBDQ-32
Medication Hospital
records
Extra intestinal
manifestations
Interview and
physical
examination
Disease course Interview
Blondel-Kucharski F.
2001
FR
[19]
PC Multicentre
Inpatients/
outpatients
1 231 231 29
(17–78)
99/132 6.3 (0.3–41.8) Socio-demographics NS SF-36
RFIPCClinical data Predefined
definition
Global disease course GDCS, VAS
Boye B.
2008
CS Multicentre
Inpatients/
– 110 54 38.1
(18–60)
14/40 NS Socio-demographics NS IBDQ-32
Personality
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der
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ave
et
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Publication
Country
Reference
age,
years
(SD, IQR)
duration,
years
(SD, IQR)
IBD CD
NOR
[20]
patient
organizations
BPA, EPQ,
LOC, TAS
Clinical data HBI
Canavan C.
2006
UK
[21]
CCS Multicentre
Outpatients
– 221 221 NS 90/131 N20 years
b10 years
Socio-demographics CDISR IBDQ-32
RFIPCClinical data Self-reported
Casellas F.
2005
ES
[22]
CS Multicentre
Primary and
tertiary
hospitals
Inpatients/
outpatients
– 1156 628 34
(26–44)
274/354 5 (1.8–13.4) Socio-demographics NS EQ-5D
IBDQ-36Clinical data HBI
Casellas F.
2005
ES
[23]
CS Multicentre
Primary and
tertiary
hospitals
Inpatients/
outpatients
– 198 198 30
(23–38)
76/122 3 (0.4–6.8) Socio-demographics NS IBDQ-36
EQ-5D
PGWB
Clinical data HBI, Vienna
Casellas F.
2001
ES
[24]
CS Inpatients/
outpatients
– 289 129 33
(24–40)
44/85 4.1 (1.2–8.3) Socio-demographics HBI PGWB
IBDQ-36Clinical data NS
Drossman D.
1989
USA
[25]
CS Inpatients/
outpatients
– 150 87 35.0 ±
12.2
33/54 11.6 ± 9.1 Socio-demographics Self-reported
questionnaire
SIP
RFIPC
Clinical data Self-reported
questionnaire,
physician
rating
Feagan F.G.
2003
Multinational
[40]
RCT
IFX single
dose
IFX 5 mg
IFX 10 mg
Multicentre
Inpatients/
outpatients
1 110
113
112
110
113
112
37 ± 12 205/130 9.6 ± 7.5 Socio-demographics NS SF-36
IBDQ-32Clinical data CDAI, Montréal
Feagan F.G.
2007
Multinational
[41]
RCT
NAT vs.
placebo
Multicentre
Inpatients/
outpatients
1.2 168
171
168
171
37 ± 13
37 ± 12
77/91
59/112
10 ± 9
10 ± 7.3
Socio-demographics NS EQ
SF
IBDQ
Clinical data CDAI, Montréal
Feagan F.G.
2009
Multinational
[26]
RCT CER
vs.
placebo
Multicentre
Inpatients/
outpatients
0.5 215
210
215
210
37.6 ±
12.1
37.5 ±
11.3
92/123
109/101
8.6 ± 7.1
7.3 ± 7.8
Socio-demographics NS EQ-5D
SF-36
IBDQ-32
WPAI
Clinical data CDAI, Montréal
Gibson P.R.
2007
CS Multicentre
Tertiary
– 143 143 38.4 ±
12.2
60/83 9.4 ± 7.4 Socio-demographics Self-reported
questionnaire
AQoL
IBDQ-32
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Table 2 (continued)
Article Study characteristics Characteristics CD participants Determinant HRQOL
First author
Year of
Publication
Country
Reference
Design Setting Follow-up,
years
Sample
size
Mean/
median
age,
years
(SD, IQR)
Sex Ratio,
M/F
Mean/median
disease
duration,
years
(SD, IQR)
Determinant Measure Questionnaire
IBD CD
AUS
[27]
hospitals
Outpatients
Clinical data CDAI
Guassora A.D.
2000
DK
[28]
CCS Outpatients – 94 94 38
(18–65)
39/55 7(0–29) Socio-demographics NS McMaster
IBDQDisease activity CDAI
Høivik M.L.
2011
NOR
[29]
PC
IBSEN Cohort
Multicentre
Outpatients
– 98 98 42 ± 13.7 57/41 10 Socio-demographics Interview/
self-reported
questionnaire
SF-36
IBDQ-32
Clinical data Interview,
Vienna
Iglesias M.
2010
ES
[30]
CS Outpatients – 92 92 37.6 ±
11.4
48/44 9.2 ± 8.1 Socio-demographics Patient
records
SF-36
IBDQ-36
Clinical data Montréal
Jaghult S.
2011
SE
[31]
CS Outpatients – 197 83 43.7 ±
13.6
36/47 7.6 ± 2.6 Socio-demographics NS IBDQ-32
RFIPCClinical data HBI
Coping SOC
(short form)
Loftus EV et al.
2008
Multinational
[32]
RCT
ADA induction
ADA 40 mg eow
ADA 40 mg
weekly
Multicentre
Inpatients/
outpatients
1 170
172
157
170
172
157
36.9 ±
11.9
36.4 ±
11.1
36.9 ±
11.8
65/105
61/111
62/95
NS Socio-demographics NS SF-36
IBDQ-32Depression Zung
Depression
Scale
Fatigue FACIT-Fatigue
Scale
Disease activity CDAI
Maunder R et al.
1999
CAN
[33]
CS Tertiary
hospital
Inpatients/
outpatients
– 343 157 36.7 149/194a NS Socio-demographics NS RFIPC
Symptom severity Self-reported
Romberg-Camps
M.J.L.
2010
NL
[34]
PC
IBD-
South-Limburg
cohort
Multicentre
Outpatients
Inpatients,
outpatients
– 707 304 40
(21–89)
104/200 8.1 (0.7–15.4) Socio-demographics NS SF-36
IBDQ-32Fatigue MFI-20
Anxiety, depression HADS
Clinical data HBI, Vienna,
medication
– 1105 545 218/327 NS Socio-demographics NS IBDQ-32
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Country
Reference
age,
years
(SD, IQR)
duration,
years
(SD, IQR)
IBD CD
Russel M.G.
1996
NL
[35]
CS
IBD-
South-Limburg
cohort
Multicentre
Outpatients
37
(13–90)
Smoking habits Self-reported
questionnaire
Schirbel A.
2010
DE
[36]
CS Multicentre
Outpatients
– 334 179 38.9 ±
11.6
71/108 9.2 (2.8–15.6) Socio-d mographics Questionnaire SIBDQ
Clinica ata CDAI
Pain GPQ, VAS
Stjernman H.
2010
SE
[37]
CS Multicentre
Outpatients
– 447 447 45
(33–55)
188/259 14 (6–25) Socio-d mographic NS SF-36
IBDQ-32
RFIPC
PGWB
SHS
Clinica ata CDAI, PGA
Straus W.L.
2000
USA
[38]
CS Multicentre
Tertiary and
private
hospitals
Outpatients
– 442 442 42.7 ±
14.6
193/249 NS Socio-d mographics Self-reported
questionnaire
SF36
Clinica ata CDAI
Race Black/white
Eijk I. van der
2004
European
[39]
CS
EC-IBD cohort
Multicentre
Outpatients
– 517 195 42
(34–56)
247/270a 6–8 Socio-d mographics NS SIBDQ
Psycho gical
distres
MHI-5
Coping CISS
Social s pport MOSSSS
Stressf life
events
SRRQ
Clinica ata HBI
Quality f care QUOTE-IBD
Disease ctivity
Abbreviations: ADA = adalimumab, AQoL = Assessment of Quality of Life, BPA = Buss–Perry Aggression Questionnaire, CCS = case–cont l study, CDISR = Crohn's disease Index for Survey
Research, CER = certolizumab, CISS = Coping Inventory of Stressful Situations, CS = cross-sectional study, EC-IBD = European Collaborat e study group on Inflammatory Bowel Disease, eow =
every other week, EPQ = Eysenck Personality Questionnaire, EQ-5D = EuroQol 5 Dimensions, GDCS = Global Disease Course Score, GPQ German Pain Questionnaire, HADS = Hospital Anxiety
Depression Scale, HBI = Harvey–Bradshaw Index, ISI = Insomnia Severity Index, LOC = Multidimensional Health Locus of Control Scale, MF = Multidimensional Fatigue Inventory, MHI-5 = Mental
Health Inventory-5, MOSSSS = Medical Outcomes Study Social Support Survey, NAT = natalizumab, NS = not specified, PC = prospective co ort study, PGA = Physicians Global Assessment, PGWB
= Psychological General Well Being Index, PSQI = Pittsburgh Sleep Quality Index, QUOTE-IBD = Quality of Care Through the IBD patient eyes, RCS = retrospective cohort study, SHS = Short
Health Scale, SIP = Sickness Impact Profile, SRRQ = Social Readjustment Rating Questionnaire, TAS = Toronto Alexithymia Scale.
a: Data from the whole study sample, including patients without Crohn's disease.
b: Repeat assessment sample.
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Figure 2 Socio-demographic determinants of disease-related HRQOL: frequency of findings.
Table 3 Overview of results from the critical appraisal.
First author Study participation Study attrition Prognostic factor Outcome Confounding Analysis Overall quality
Ananthakrishnan 1 x 1 1 2 2 1
Andersson 1 x 2 1 3 2 2
Banovic 3 2 1 1 3 2 3
Bernklev 2006 1 2 1 1 2 1 1
Bernklev 2005 1 2 2 1 1 1 1
Bernklev 2004 1 2 2 1 2 1 1
Blondel–Kucharski 2 2 2 1 1 2 2
Boye 1 x 1 1 2 2 1
Canavan 1 x 1 1 2 2 1
Casellas 2005 2 x 1 1 2 1 1
Casellas 2005 2 x 1 1 2 1 1
Casellas 2001 1 x 1 1 2 2 2
Drossman 2 x 2 1 3 2 2
Feagan 2009 1 2 2 1 2 2 2
Feagan 2007 1 2 2 1 2 2 2
Feagan 2003 1 2 2 1 2 2 2
Gibson 1 x 2 1 2 2 2
Guassora 1 x 1 1 3 2 2
Høivik 1 2 1 1 2 1 1
Iglesias 1 x 1 1 2 3 2
Jaghult 2 x 1 1 2 2 2
Loftus 1 2 2 1 2 2 2
Maunder 2 x 3 1 3 2 3
Romberg 1 2 1 1 2 1 1
Russel 1 x 1 1 3 2 2
Schirbel 1 x 1 1 3 2 2
Stjernman 2 x 1 1 2 1 1
Straus 2 x 1 1 1 1 1
Van der Eijk 3 x 2 1 1 1 2
1 = low risk for bias, 2 = moderate risk for bias, 3 = high risk for bias, x = not applicable.
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p<0.05 p>0.05 Not assessed
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Figure 3 Clinical determinants of disease-related HRQOL: frequency of findings.
103Determinants of HRQOL in Crohn's diseasecharacteristics of adult IBD patients, yielding 107 relevant
studies.5 This remarkably high number of included studies is
mainly attributable to including studies of mixed IBD
populations and studies with small sample sizes (b50
patients), which were excluded in our study. In their review,
Sainsbury et al. found a number of psychological and social
factors to be related with a lower HRQOL in IBD patients,
including female gender, lower socioeconomic status,
ethnicity and perceived stress.5 In line with our results,
female gender was associated with a lower HRQOL. Several
hypotheses for this finding exist. Psychosocial factors may
play a greater role in females than in males.19 Others state
that females have greater disease-related concerns and0 5
p<0.05
CD-related surgery
Corticosteroids
Immunosuppressants
Biologicals
CD-related hospitalisation
5-ASA
Figure 4 Treatment-related determinants of dworries about being a burden of being treated differently as
a result of their illness.46 Furthermore, females are also
more likely to report concerns related to attractiveness,
body image and feeling alone.33 Noteworthy, females also
report poorer HRQOL than males across various chronic
illnesses — including asthma,47 rheumatoid arthritis48 and
diabetes49 and even in the general healthy population.50
The negative influence of low socioeconomic status,
ethnicity and higher perceived stress on HRQOL in CD patients
could not be corroborated in our study, as these factors were
reported by any of the included studies.
Psychological factors, such as illness perceptions and
psychological distress (anxiety and depression), were10
p>0.05 Not assessed
Number of studies
15 20 25
isease-related HRQOL: frequency of findings.
104 M. van der Have et al.underrepresented in the included articles, but warrant further
research. Previous studies in IBD have found that illness
perceptions contributed to 4–21% of patients' HRQOL, in
addition to socio-demographic and clinical determinants.51–53
More importantly, as these illness perceptions are modifiable,
they provide potential targets for HRQOL enhancing interven-
tions. In addition, anxiety and depression are highly prevalent
in IBD patients, and have been found to be related with
HRQOL.39,54–56
HRQOL was significantly impaired by work disability in two
out of three studies. Noteworthy, work disability rates of IBD
patients range between 1.3 and 34%,13,16,57–63 with even
higher rates in CD patients under 40 years of age.63 As work
disability leads to a heavy psychosocial and financial burden
for patients, all efforts should be made to prevent work
disability and to help work disabled patients back into the
labour market.
Although we found a negative association between corti-
costeroid treatment and HRQOL in four out of nine studies,
this finding should be interpretedwith caution. First of all, this
negative association was mainly based on cross-sectional
studies, thereby, a potential positive or negative influence
of corticosteroid treatment on HRQOL over time could not be
determined.20,35,38 Furthermore, not all studies appropriately
corrected for disease activity, making it impossible to
determine an independent association between corticosteroid
treatment and HRQOL.19,38 It is known that corticosteroids are
frequently associated with specific side effects, including
cosmetic side effects and sleep andmood disturbances, with a
possible negative effect on HRQOL.64 However, whether these
corticosteroid-specific side effects are responsible for the
negative association between corticosteroid use and HRQOL
remains a matter of debate. As HRQOL measures have been
available in IBD management since the early 1980s, appropri-
ate studies assessing the influence of conventional immuno-
suppressants, such as thiopurines and methotrexate, on CD
patients' HRQOL were lacking. The available evidence from
our analyses that HRQOL is positively influenced by biological
treatment is relatively strong, as this evidence was mainly
based on prospective randomized studies.26,32,40,41 Further
non-randomized prospective studies are warranted to validate
the positive impact of biological treatment on HRQOL in daily
clinical practice.
Our study has several important strengths. The strength
of the association between any of the determinants and
HRQOL was assessed, indicating which of the variables
significantly contributed to the HRQOL of CD patients. In
addition, evidence on the determinants of HRQOL in CD is
systematically summarized and critically appraised, showing
all evidence available and revealing areas in which further
research is required. As stated in the Introduction, a
comprehensive understanding of the determinants of
HRQOL may guide clinical decision making. Important
clinical decision, such as top-down versus step-up therapy,
ileocolonic resection versus anti-TNF therapy and anti-TNF
mono-therapy versus combination anti-TNF plus thiopurine
therapy, should ideally be based on this kind of evidence, as
these decisions may have significant consequences to
patients' daily lives.
Our study has some limitations as well. As we included
studies with heterogeneous sample sizes, study designs,
determinant and outcome measures, we were unable toquantify the relationships between other determinants,
besides disease activity, and HRQOL. Although the pooled
association between disease activity and HRQOL was
relatively strong, this finding should be interpreted with
caution as the meta-analysis indicated significant heteroge-
neity across the included studies. Furthermore, as we
excluded abstracts and unpublished studies, publication
bias cannot be completely ruled out. However, as most of
the available and reviewed studies had a moderate to high
quality, we feel that the contribution of unpublished studies
would be minimal. Of note, all randomized controlled trials
received financial support by a pharmaceutical company,
which might suggest publication bias. However, none these
companies were involved in the data analysis.
In conclusion, determinants that were found to consistent-
ly impact the HRQOL of adult CD patients, included markers of
active disease such as work disability, clinical disease activity,
increased relapse rate, biological treatment and hospitaliza-
tion. Unfortunately, these determinants are not very helpful
for clinicians when dealing with asymptomatic CD patients or
when choosing between treatmentswith a comparable clinical
efficacy (for example clinical remission). As disease activity
contributed to only 37% of HRQOL, there remains a need for
additional, possibly modifiable, determinants. Therefore, in
order to improve our understanding of HRQOL and to facilitate
clinical decision making, more long-term prospective data on,
preferably, modifiable determinants of HRQOL are highly
needed. Ultimately, this will improve HRQOL in an important
subset of patients, leading to a decrease in health care and
society costs.65Contributors
MH and KA contributed to study concept and design,
acquisition, analysis and interpretation of data. HF, AK and
BO contributed to interpretation of data. MH, KA and ML
contributed to statistical analysis. All authors contributed to
drafting of the manuscript.Conflict of interest statement
The authors declare no conflict of interest.Acknowledgement
We acknowledge Bianca M.R. Kramer, librarian, for her expert
assistance in designing the search strategy.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.crohns.2013.04.007.References
1. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. The
natural history of adult Crohn's disease in population-based
cohorts. Am J Gastroenterol 2010;105:289–97.
105Determinants of HRQOL in Crohn's disease2. Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory
bowel disease. J Clin Gastroenterol 1992;14:15–9.
3. Schipper H, Clinch JJ, Olweny CLM. Quality of life studies:
definitions and conceptual issues. In: Spilker B, editor. Quality
of Life and Pharmacoeconomics in Clinical Trials. ed. 2.
Philadelphia: Lippincott-Raven Press; 1996. p. 11–23.
4. Cohen RD. The quality of life in patients with Crohn's disease.
Aliment Pharmacol Ther 2002;16:1603–9.
5. Sainsbury A, Heatley RV. Review article: psychosocial factors in
the quality of life of patients with inflammatory bowel disease.
Aliment Pharmacol Ther 2005;21:499–508.
6. Mussel, Böcker U, Nagel N, Singer MV. Predictors of disease
related concerns and other aspects of health-related quality of
life in outpatients with inflammatory bowel disease. Eur J
Gastroenterol Hepatol 2004;16:1273–80.
7. Graff LA, Walker JR, Lix L, Clara I, Rawsthorne P, Rogala L,
et al. The relationship of inflammatory bowel disease type and
activity to psychological functioning and quality of life. Clin
Gastroenterol Hepatol 2006;4:1491–501.
8. Altman DG. Systematic reviews of evaluations of prognostic
variables. BMJ 2001;323:224–8.
9. Eisen GM, Locke GR, Provenzale D. Health-related quality of life:
a primer for gastroenterologists. Am J Gastroenterol 1999;94:
2017–21.
10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC,
Ioannidis JP, et al. The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate
healthcare interventions: explanation and elaboration. BMJ
2009;339:b2700.
11. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of
prognosis studies in systematic reviews. Ann Intern Med
2006;144:427–37.
12. R Development Core Team. R: a language and environment
for statistical computing. Vienna, Austria: R Foundation for
Statistical Computing3-900051-07-0; 2008 [URL, http://www.
R-project.org].
13. Ananthakrishnan AN, Weber LR, Knox JF, Skaros S, Emmons J,
Lundeen S, et al. Permanent work disability in Crohn's disease.
Am J Gastroenterol 2008;103:154–61.
14. Andersson P, Olaison G, Bendtsen P, Myrelid P, Sjodahl R.
Health related quality of life in Crohn's proctocolitis does not
differ from a general population when in remission. Colorectal
Dis 2003;5:56–62.
15. Banovic I, Gilibert D, Cosnes J. Crohn's disease and fatigue:
constancy and co-variations of activity of the disease, depres-
sion, anxiety and subjective quality of life. Psychol Health Med
2010;15:394–405.
16. Bernklev T, Jahnsen J, Henriksen M, Lygren I, Aadland E, Sauar
J, et al. Relationship between sick leave, unemployment,
disability, and health-related quality of life in patients with
inflammatory bowel disease. Inflamm Bowel Dis 2006;12:
402–12.
17. Bernklev T, Jahnsen J, Aadland E, Sauar J, Schulz T, Lygren I,
et al. Health-related quality of life in patients with inflamma-
tory bowel disease five years after the initial diagnosis. Scand J
Gastroenterol 2004;4:365–73.
18. Bernklev T, Jahnsen J, Schulz T, Sauar J, Lygren I, Henriksen M,
et al. Course of disease, drug treatment and health-related
quality of life in patients with inflammatory bowel disease
5 years after initial diagnosis. Eur J Gastroenterol Hepatol
2005;17:1037–45.
19. Blondel-Kucharski F, Chircop C, Marquis P, Cortot A, Baron F,
Gendre JP, et al. Health-related quality of life in Crohn's
disease: a prospective longitudinal study in 231 patients. Am J
Gastroenterol 2001;96:2915–20.
20. Boye B, Jahnsen J, Mokleby K, Leganger S, Jantschek G,
Jantschek I, et al. The INSPIRE study: are different personality
traits related to disease-specific quality of life (IBDQ) indistressed patients with ulcerative colitis and Crohn's disease?
Inflamm Bowel Dis 2008;14:680–6.
21. Canavan C, Abrams KR, Hawthorne B, Drossman D, Mayberry JF.
Long-term prognosis in Crohn's disease: factors that affect
quality of life. Aliment Pharmacol Ther 2006;23:377–85.
22. Casellas F, Arenas JI, Baudet JS, Fábregas S, García N, Gelabert
J, et al. Impairment of health-related quality of life in patients
with inflammatory bowel disease: a Spanish multicenter study.
Inflamm Bowel Dis 2005;11:488–96.
23. Casellas F, López-Vivancos J, Sampedro M, Malagelada JR.
Relevance of the phenotypic characteristics of Crohn’s disease
in patient perception of health-related quality of life. Am J
Gastroenterol 2005;100:2737–42.
24. Casellas F, López-Vivancos J, Badia X, Vilaseca J, Malagelada J.
Influence of inflammatory bowel disease on different dimen-
sions of quality of life. Eur J Gastroenterol Hepatol 2001;13:
567–72.
25. Drossman DA, Patrick DL, Mitchell CM, Zagami EA, Appelbaum
MI. Health-related quality of life in inflammatory bowel
disease. Functional status and patient worries and concerns.
Dig Dis Sci 1989;34:1379–86.
26. Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S.
Clinically meaningful improvement in health-related quality of
life in a randomized controlled trial of certolizumab pegol
maintenance therapy for Crohn's disease. Am J Gastroenterol
2009;104:1976–83.
27. Gibson PR, Weston AR, Shann A, Florin TH, Lawrance IC, Macrae
FA, et al. Relationship between disease severity, quality of life
and health-care resource use in a cross-section of Australian
patients with Crohn's disease. J Gastroenterol Hepatol 2007;22:
1306–12.
28. Guassora AD, Kruuse C, Thomsen OO, Binder V. Quality of life
study in a regional group of patients with Crohn’s disease. A
structured interview study. Scand J Gastroenterol 2000;35:
1068–74.
29. Høivik ML, Bernklev T, Solberg IC, Cvancarova M, Lygren I,
Jahnsen J, et al. Patients with Crohn's disease experience
reduced general health and vitality in the chronic stage:
ten-year results from the IBSEN study. J Crohns Colitis 2012;6:
441–53.
30. Iglesias M, Vazquez I, Barreiro-de Acosta M, Figueiras A, Nieto L,
Piñeiro M, et al. Health related quality of life in patients with
Crohn’s disease in remission. Rev Esp Enferm Dig 2010;102:
624–30.
31. Jaghult S, Saboonchi FJ, Unn B, Wredling R, Kapraali M.
Identifying predictors of low health-related quality of life
among patients with inflammatory bowel disease: comparison
between Crohn's disease and ulcerative colitis with disease
duration. J Clin Nurs 2011;20:1578–87.
32. Loftus EV, Feagan BG, Colombel JF, Rubin DT,Wu EQ, Yu AP, et al.
Effects of adalimumab maintenance therapy on health-related
quality of life of patients with Crohn's disease: patient-reported
outcomes of the CHARM trial. Am J Gastroenterol 2008;103:
3132–41.
33. Maunder R, Toner B, de Rooy E, Moskovitz D. Influence of sex
and disease on illness-related concerns in inflammatory bowel
disease. Can J Gastroenterol 1999;13:728–32.
34. Romberg-Camps MJ, Bol Y, Dagnelie PC, Hesselink-van de Kruijs
MA, Kester AD, Engels LG, et al. Fatigue and health-related
quality of life in inflammatory bowel disease: results from a
population-based study in the Netherlands: the IBD-South
Limburg cohort. Inflamm Bowel Dis 2010;16:2137–47.
35. Russel MG, Nieman FH, Bergers JM, Stockbrügger RW. Cigarette
smoking and quality of life in patients with inflammatory bowel
disease. South Limburg IBD Study Group. Eur J Gastroenterol
Hepatol 1996;8:1075–81.
36. Schirbel A, Reichert A, Roll S, Baumgart DC, Büning C, Wittig B,
et al. Impact of pain on health-related quality of life in patients
106 M. van der Have et al.with inflammatory bowel disease. World J Gastroenterol
2010;16:3168–77.
37. Stjernman H, Tysk C, Almer S, Strom M, Hjortswang H. Worries
and concerns in a large unselected cohort of patients with
Crohn's disease. Scand J Gastroenterol 2010;45:696–706.
38. Straus WL, Eisen GM, Sandler RS, Murray SC, Sessions JT. Crohn's
disease: does race matter? The Mid-Atlantic Crohn's Disease
Study Group. Am J Gastroenterol 2000;95:479–83.
39. Van der Eijk I, Vlachonikolis IG, Munkholm P, Nijman J, Bernklev
T, Politi P, et al. The role of quality of care in health-related
quality of life in patients with IBD. Inflamm Bowel Dis 2004;10:
392–8.
40. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects
of infliximab maintenance therapy on health-related quality of
life. Am J Gastroenterol 2003;98:2232–8.
41. Feagan BG, Sandborn WJ, Hass S, Niecko T, White J.
Health-related quality of life during natalizumab maintenance
therapy for Crohn's disease. Am J Gastroenterol 2007;102:
2737–46.
42. Tillinger W, Mittermaier C, Lochs H, Moser G. Health-related
quality of life in patients with Crohn's disease: influence of
surgical operation — a prospective trial. Dig Dis Sci 1999;44:
932–8.
43. Solberg IC, Vatn MH, Hoie O, Stray N, Sauar J, Jahnsen J, et al.
Clinical course in Crohn's disease: results of a Norwegian
population-based ten-year follow up study. Clin Gastroenterol
Hepatol 2007;5:1430–8.
44. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R,
Hiele M. Predictability of the postoperative course of Crohn's
disease. Gastroenterology 1990;99:956–63.
45. Dhillon SL, Loftus Jr EV, Tremaine WJ. The natural history of
surgery for Crohn‘s disease in a population-based cohort from
Olmsted County, Minnesota (Abstract 825). Am J Gastroenterol
2005;100:S305.
46. Moser G, Tillinger W, Sachs G, Genser D, Maier-Dobersberger T,
Spiess K, et al. Disease-related worries and concerns: a study on
out-patients with inflammatory bowel disease. Eur J
Gastroenterol Hepatol 1995;7:853–8.
47. Wijnhoven HAH, Kriegsman DM, Snoek FJ, Hesselink AE, de Haan
M. Gender differences in health-related quality of life among
asthma patients. J Asthma 2003;40:189–99.
48. Dowdy SW, Dwyer KA, Smith CA, Wallston KA. Gender and
psychological well-being of persons with rheumatoid arthritis.
Arthritis Care Res 1996;9:449–56.
49. Petterson T, Lee P, Hollis S, Young B, Newton P, Dornan T.
Well-being and treatment satisfaction in older people with
diabetes. Diabetes Care 1998;21:930–5.
50. Stewart AL, Hays RD, Ware JE. The MOS short-form general
health survey. Reliability and validity in a patient population.
Med Care 1988;26:724–35.
51. Dorrian A, Dempster M, Adair P. Adjustment to inflammatory
bowel disease: the relative Influence of illness perceptions and
coping. Inflamm Bowel Dis 2009;15:47–55.
52. Han SW, McColl E, Barton JR, James P, Steen IN, Welfare MR.
Predictors of quality of life in ulcerative colitis. The importanceof symptoms and illness representations. Inflamm Bowel Dis
2005;11:24–34.
53. Rochelle TL, Fidler H. The importance of illness perceptions,
quality of life and psychological status in patients with
ulcerative colitis and Crohn’s disease. J Health Psychol Oct 1
2012, http://dx.doi.org/10.1177/1359105312459094 [Epub
ahead of print].
54. Guthrie E, Jackson J, Shaffer J, Thompson D, Tomenson B,
Creed F. Psychological disorder and severity of inflammatory
bowel disease predict health-related quality of life in ulcerative
colitis and Crohn's disease. Am J Gastroenterol 2002;97:
1994–9.
55. Vidal A, Gómez-Gil E, Sans M, Portella MJ, Salamero M, Piqué
JM, et al. Health-related quality of life in inflammatory bowel
disease patients: the role of psychopathology and personality.
Inflamm Bowel Dis 2008;14:977–83.
56. Janke KH, Klump B, Gregor M, Meisner C, Haeuser W. De-
terminants of life satisfaction in inflammatory bowel disease.
Inflamm Bowel Dis 2003;11:272–86.
57. Feagan BG, Bala M, Yan S, Olson A, Hanauer S. Unemployment
and disability in patients with moderately to severely active
Crohn's disease. J Clin Gastroenterol 2005;39:390–5.
58. Boonen A, Dagnelie PC, Feleus A, Hesselink MA, Muris JW,
Stockbrügger RW, et al. The impact of inflammatory bowel
disease on labor force participation: results of a population
sampled case–control study. Inflamm Bowel Dis 2002;8:382–9.
59. Bernstein CN, Kraut A, Blanchard JF, Rawsthorne P, Yu N, Walld
R. The relationship between inflammatory bowel disease and
socioeconomic variables. Am J Gastroenterol 2001;96:2117–25.
60. Sonnenberg A. Disability and need for rehabilitation among
patients with inflammatory bowel disease. Digestion 1992;51:
168–78.
61. Stjernman H, Tysk C, Almer S, Ström M, Hjortswang H.
Unfavourable outcome for women in a study of health-related
quality of life, social factors and work disability in Crohn's
disease. Eur J Gastroenterol Hepatol 2011;23:671–9.
62. van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van
Bodegraven AA, Fidder HH, et al. Healthcare costs of inflam-
matory bowel disease have shifted from hospitalisation and
surgery towards anti-TNFα therapy: results from the COIN
study. Gut 2012, http://dx.doi.org/10.1136/gutjnl-2012-
303376.
63. Høivik ML, Moum B, Solberg IC, Henriksen M, Cvancarova M,
Bernklev T, et al. Work disability in inflammatory bowel disease
patients 10 years after disease onset: results from the IBSEN
Study. Gut 2013, http://dx.doi.org/10.1136/gutjnl-2012-
302311.
64. Singleton JW, Law DH, Kelley Jr ML, Mekhjian HS, Sturdevant
RA. National Cooperative Crohn's Disease Study: adverse re-
actions to study drugs. Gastroenterology 1979;77:870–82.
65. De Boer A, Sprangers M, Bartelsman J, de Haes H. Predictors of
health care utilization in patients with inflammatory bowel
disease: a longitudinal study. Eur J Gastroenterol Hepatol
1998;10:783–9.
